Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30436820 | 1.00 | HSD17B10 (0.71) | HSD17B10POLBADRA1ATAAR1MTNR1A | |
| SCHEMBL11433418 | 0.90 | HSD17B10 (0.67) | HSD17B10POLBADRA1ATAAR1MTNR1A | |
| SCHEMBL27621740 | 0.89 | HSD17B10 (0.65) | HSD17B10POLBADRA1ATAAR1MTNR1A | |
| SCHEMBL7332981 | 0.88 | HSD17B10 (0.63) | HSD17B10POLBADRA1ATAAR1MTNR1A | |
| SCHEMBL10909359 | 0.88 | POLB (0.60) | HSD17B10POLBADRA1ATAAR1MTNR1A | |
| SCHEMBL490637 | 0.87 | POLB (0.71) | HSD17B10POLB | |
| SCHEMBL11077966 | 0.87 | MTNR1A (0.62) | HSD17B10POLBADRA1ATAAR1MTNR1A | |
| SCHEMBL64208 | 0.85 | MTNR1A (0.61) | HSD17B10ADRA1ATAAR1MTNR1AMTNR1B | |
| SCHEMBL7368806 | 0.85 | POLB (0.79) | HSD17B10POLBMTNR1AMTNR1B | |
| SCHEMBL7190492 | 0.84 | HSD17B10 (0.59) | HSD17B10ADRA1ATAAR1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-116077553-B | Dressing containing walnut shell extract for promoting wound healing and preparation method thereof | 西安交通大学 | 2024-05-24 | — | — | CN | disclosed |
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117642379-A | Phenylalkylamines and methods of making and using the same | 吉尔伽美什制药公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116077553-A | Application of walnut shell extract in promoting wound healing, wound dressing based on walnut shell extract and preparation method of wound dressing | 西安交通大学 | 2023-05-09 | — | — | CN | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | NOVO NORDISK A/S (DK) | 2020-12-31 | — | — | US | disclosed |
| US-10456472-B2 | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2114145-B1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECH INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-1061919-A4 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RES TRIANGLE INST (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1061919-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | Carrol, Frank Ivy (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999045925-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5087671-A | Insoluble polymers containing reactive groups | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1992-02-11 | — | — | US | disclosed |
| US-5066658-A | Enzyme Inhibitors; Bronchodilators; Antiinflammatory Agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-11-19 | — | — | US | disclosed |
| US-4231950-A | PHOTOGRAPHY | POLAROID CORPORATION (US) | 1980-11-04 | — | — | US | disclosed |
| US-4206139-A | Synthesis of benzaldehydes | POLAROID CORPORATION (US) | 1980-06-03 | — | — | US | disclosed |
| US-4166741-A | FOR SELF-DEVELOPING PHOTOGRAPHIC FILMS | POLAROID CORPORATION (US) | 1979-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | HSD17B10 1647/4885POLB 3555/4885ADRA1A 2293/4885 |
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | PNMT, HTR6, HTR2C | HSD17B10 917/4885POLB 1731/4885ADRA1A 640/4885 |
| US-10456472-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | HSD17B10 1647/4885POLB 3555/4885ADRA1A 2293/4885 |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | HSD17B10 1647/4885POLB 3555/4885ADRA1A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.